Macrophage Pharma has an expanding pipeline of new chemical entity (NCE) assets leveraging the ESM™ targeting platform to shape macrophage biology in multiple diseases including cancer, liver injury, fibrosis and other autoimmune diseases where macrophages are centrally involved.